AICAR
guinea pig
The Dose Guy’s verdictSep 1, 20263 sources
The mechanism is real: AICAR activates AMPK, the energy sensor that exercise flips, and the animal data on fat oxidation, glucose handling, and endurance is genuine. The problem is physics. The doses that work in mice translate to tens of grams subcutaneously in a human, volumes nobody can practically inject. The community tries 50 to 150 mg subcutaneously and hopes for the best, but that is a gesture, not a protocol. Skip it for fat loss. Retatrutide and tirzepatide solve the problem at doses you can actually inject.
What it is
A purine nucleoside analog, acadesine, that gets phosphorylated inside cells to ZMP, which mimics AMP and flips the AMPK switch. AMPK is the sensor that tells your cells energy is low, the same signal exercise sends: burn fat, take up glucose, build mitochondria, stop storing. That is why the “exercise in a pill” headlines write themselves and why AICAR carries a WADA ban despite never being developed as an athletic drug.
The human data that exists is from cardiac surgery, not from fat loss. Acadesine was tested intravenously in thousands of bypass patients to protect the heart during the operation, and even there the largest trial stopped for futility. On the weight-loss shelf AICAR has the most interesting mechanism and the least practical path to using it, while retatrutide and tirzepatide solve fat loss through appetite pathways with massive human evidence bases and a subcutaneous injection you can actually do at home.
What the research shows
Substantial human data exists, all from the wrong context. The exercise-mimetic story is animal-only:
Realistic protocols
The dose problem is the whole story. Mouse studies run 300 to 500 mg/kg subcutaneously. For a 75 kg human, that is 22 to 37 grams per day. Nobody is injecting that volume. The community protocol, 50 to 150 mg sub-q daily, is roughly a thousandth of the animal dose, and there is no human pharmacodynamic data showing that dose does anything to AMPK in muscle or fat tissue. A detection study gave two men 3 g of AICAR orally for urine testing, but that was an analytical exercise, not a dosing trial. You are essentially microdosing a compound that needed a firehose to work in mice. WADA bans it above a urinary threshold, which means athletes are trying, but a ban is not evidence of efficacy at community doses.
Side effects
At the doses people actually try, side effects are mostly unknown. At the IV doses from the cardiac trials:
